FDA Accepting Less Data, More Surrogate Endpoints in Trials FDA Accepting Less Data, More Surrogate Endpoints in Trials

Less stringent clinical trial requirements and expedited pathways have come with positive and negative results, an editorialist writes. He suggests ways to reform the reform.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Family Medicine/Primary Care News Source Type: news